Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older.
- People who have been diagnosed with non-small cell lung cancer (a common type of lung cancer), confirmed through a tissue test.
- People who are currently receiving immunotherapy treatment and have been on it for at least one month.
- People who are planned to continue immunotherapy for at least 24 weeks from the time of joining the study.
- People with a general fitness and activity level rated between 0 and 2 on a standard oncology scale, meaning they are able to complete physical fitness and function assessments (confirm with trial site).
- People who are able to understand the study information and are willing to give their consent to participate.
Who may not be able to join:
- People who are already doing 150 minutes or more of moderate-to-vigorous exercise per week on a regular basis over the past month, as the trial is specifically looking at people who are not very active.
- People with certain unstable or uncontrolled medical conditions that the study team, together with the treating cancer doctor, considers too risky for exercise participation — this includes things like a recent heart attack (within the last 6 months), uncontrolled heart rhythm problems, severe heart failure, unstable chest pain, severely high blood pressure, poorly controlled diabetes, severe lung disease requiring hospitalisation in the past 3 months, or bone cancer spread with a high risk of fracture (confirm with trial site for the full list).
- People considered at high risk of not being able to follow the study requirements, such as those with a history of three or more missed cancer appointments without notice in the past six months, repeated failure to respond to study communications during recruitment, difficulty following instructions during the sign-up process, or concerns raised by the referring doctor.
- People who do not speak English, where this would prevent them from completing the participant survey.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dong-Woo Kang, PhD, Fred Hutch/University of Washington Cancer Consortium
Phone: 206-667-5188
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean difference in neutrophil-to-lymphocyte ratio (NLR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.